Paper Details

  1. Home
  2. Paper Details

A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study.

Author: , BorgninoCarlo, CapuanoVincenzo, MalaccoEttore, PalatiniPaolo, SpagnuoloVitaliano, VarìNatale

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compares the antihypertensive efficacy and safety of valsartan, an angiotensin II receptor blocker, and amlodipine besylate, a calcium channel blocker. While both drugs exhibit dose-related antihypertensive efficacy, amlodipine besylate is associated with possible dose-limiting adverse effects, particularly peripheral edema, whereas valsartan exhibits minimal dose-limiting adverse effects.
Paper Details　
Original Abstract of the Article :
Some antihypertensive therapies are limited by dose-dependent adverse effects (AEs). The angiotensin II receptor blocker valsartan has been shown to reduce blood pressure (BP) in a dose-related manner with minimal dose-limiting AEs. Amlodipine besylate is a potent dihydropyridine calcium channel blo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0149-2918(03)80332-6

データ提供：米国国立医学図書館（NLM）

Choosing the Right Antihypertensive Therapy

[Hypertension], or high blood pressure, is a widespread health concern, often requiring long-term medication to manage. However, some antihypertensive therapies have dose-dependent side effects, making it challenging to find the optimal treatment. This research compares the efficacy and tolerability of [valsartan], an angiotensin II receptor blocker, and [amlodipine besylate], a calcium channel blocker, in treating [isolated systolic hypertension] in elderly patients. The study aimed to evaluate the effectiveness of both drugs while minimizing the occurrence of dose-limiting side effects.

Valsartan Emerges as a Favorable Option

This study found that [valsartan] effectively lowered blood pressure in a dose-related manner with minimal dose-limiting side effects. In contrast, [amlodipine besylate], while effective, was associated with a higher risk of peripheral edema, a common side effect of calcium channel blockers. This suggests that [valsartan] may be a preferable option for treating [isolated systolic hypertension] in elderly patients, balancing efficacy with a lower risk of dose-limiting side effects.

Balancing Blood Pressure Control and Side Effects

This research highlights the importance of choosing the right antihypertensive therapy, considering individual patient factors and the potential for side effects. While both [valsartan] and [amlodipine besylate] effectively lowered blood pressure, the study suggests that [valsartan] may offer a more favorable risk-benefit profile, especially for elderly patients. This research underscores the need for personalized medicine, tailoring treatment to individual needs and preferences.

Dr.Camel's Conclusion

This research, like a wise camel choosing the safest path through the desert, guides us towards a more personalized approach to [hypertension] treatment. By understanding the individual characteristics of different antihypertensive therapies, we can better manage this common health concern, ensuring that patients can navigate their journey to good health with minimal obstacles and side effects.

Date :
  1. Date Completed 2004-03-25
  2. Date Revised 2019-09-22
Further Info :

Pubmed ID

14693303

DOI: Digital Object Identifier

10.1016/s0149-2918(03)80332-6

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.